88 related articles for article (PubMed ID: 15752739)
1. Psychological stress induces chemoresistance in breast cancer by upregulating mdr1.
Su F; Ouyang N; Zhu P; Ouyang N; Jia W; Gong C; Ma X; Xu H; Song E
Biochem Biophys Res Commun; 2005 Apr; 329(3):888-97. PubMed ID: 15752739
[TBL] [Abstract][Full Text] [Related]
2. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
3. Adrenaline induces chemoresistance in HT-29 colon adenocarcinoma cells.
Yao H; Duan Z; Wang M; Awonuga AO; Rappolee D; Xie Y
Cancer Genet Cytogenet; 2009 Apr; 190(2):81-7. PubMed ID: 19380024
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance in chemotherapy for breast cancer.
Saeki T; Tsuruo T; Sato W; Nishikawsa K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
[TBL] [Abstract][Full Text] [Related]
5. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
6. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
[TBL] [Abstract][Full Text] [Related]
7. Stress hormones mediate drug resistance to paclitaxel in human breast cancer cells through a CDK-1-dependent pathway.
Flint MS; Kim G; Hood BL; Bateman NW; Stewart NA; Conrads TP
Psychoneuroendocrinology; 2009 Nov; 34(10):1533-41. PubMed ID: 19560278
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
9. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells.
Yu ST; Chen TM; Tseng SY; Chen YH
Biochem Biophys Res Commun; 2007 Jun; 358(1):79-84. PubMed ID: 17482571
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs.
Baker EK; Johnstone RW; Zalcberg JR; El-Osta A
Oncogene; 2005 Dec; 24(54):8061-75. PubMed ID: 16091741
[TBL] [Abstract][Full Text] [Related]
12. Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter.
Gao P; Zhou GY; Guo LL; Zhang QH; Zhen JH; Fang AJ; Lin XY
Cancer Lett; 2007 Oct; 256(1):81-9. PubMed ID: 17637500
[TBL] [Abstract][Full Text] [Related]
13. Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors.
Joo KM; Song SY; Park K; Kim MH; Jin J; Kang BG; Jang MJ; Lee GS; Kim MS; Nam DH
Int J Oncol; 2008 Oct; 33(4):705-12. PubMed ID: 18813783
[TBL] [Abstract][Full Text] [Related]
14. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
15. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
16. Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors.
Gan HZ; Zhang GZ; Zhao JS; Zhang FC; Bu LS; Yang SJ; Piao SL; Du ZW; Gao S; Zheng DM
Chin Med J (Engl); 2005 Jun; 118(11):893-902. PubMed ID: 15978189
[TBL] [Abstract][Full Text] [Related]
17. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.
Pajic M; Iyer JK; Kersbergen A; van der Burg E; Nygren AO; Jonkers J; Borst P; Rottenberg S
Cancer Res; 2009 Aug; 69(16):6396-404. PubMed ID: 19654309
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein.
Shi Z; Liang YJ; Chen ZS; Wang XH; Ding Y; Chen LM; Fu LW
Oncol Rep; 2007 Apr; 17(4):969-76. PubMed ID: 17342344
[TBL] [Abstract][Full Text] [Related]
19. Egr-1 enhances drug resistance of breast cancer by modulating MDR1 expression in a GGPPS-independent manner.
Tao W; Shi JF; Zhang Q; Xue B; Sun YJ; Li CJ
Biomed Pharmacother; 2013 Apr; 67(3):197-202. PubMed ID: 23478574
[TBL] [Abstract][Full Text] [Related]
20. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.
Newman SP; Foster PA; Stengel C; Day JM; Ho YT; Judde JG; Lassalle M; Prevost G; Leese MP; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2008 Jan; 14(2):597-606. PubMed ID: 18223236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
